Загрузка...
Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study
BACKGROUND/AIM: Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. METHODS: In a 1-year, randomized, double-blind, placebo-controlled, parallel trial...
Сохранить в:
| Опубликовано в: : | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4846053/ https://ncbi.nlm.nih.gov/pubmed/27143873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S103105 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|